Several innovative products by Luye Pharma Group (HKG:2186) have been included in the National Reimbursement Drug List for basic medical insurance, work-related injury insurance, and maternity insurance, a Thursday bourse filing said.
Antidepressant Ruoxinlin has been included in the list for the time, cancer drug Baituowei has made it for a new indication for breast cancer, and tumor drug Lipusu is included in the regular catalogue of the list.
The list will officially take effect on Jan. 1, 2025.